RAD51D and ovarian cancer: The estimated risk associated with RAD51C and RAD51D were odd ratios of 5.2 (95% CI, 1.1 to 24) and 12 (95% CI, 1.5–90), respectively [16], and confirmed their strong association with ovarian cancer [17].